The purinergic receptor P2RY12 is a clinical target in both cardiovascular and cerebrovascular diseases, since the inhibition of platelet P2RY12 prevents ADP-induced platelet aggregation and thereby reduces the risk of thrombosis [29]. This evidence concerns the gene P2RY12 and cerebrovascular disorder.